Stem Cell Research Newswire

Stem Cell Research Newswire

Comprehensive Real-Time News Feed for Stem Cell Research.

Results 1 - 20 of 6,071 in Stem Cell Research

  1. Ezogabine treatment reduces motor neuron excitability in ALS patients, study showsRead the original story w/Photo

    6 hrs ago | Medical News

    Brian Wainger, MD, PhD, of the Healey Center for ALS at Massachusetts General Hospital presented initial, top-level results of a recently completed phase 2 clinical trial of ezogabine on December 9 at the Motor Neurone Disease Association annual meeting in Glasgow, Scotland. The trial met its primary goal of measuring a reduction in motor neuron excitability in people with amyotrophic lateral sclerosis following treatment.

    Comment?

  2. NIH to fund research into fetal tissue alternativesRead the original story w/Photo

    11 hrs ago | The Hill

    The National Institutes of Health is looking for alternatives to fetal tissue in research projects after facing pressure from anti-abortion groups. NIH announced Monday a new program that would spend up to $20 million over two years to find and develop alternatives to using fetal tissue in research projects.

    Comment?

  3. BioRestorative Therapies (BRTX) vs. Tivity Health (TVTY) Head-To-Head AnalysisRead the original story w/Photo

    11 hrs ago | IntersportsWire

    BioRestorative Therapies and Tivity Health are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership. BioRestorative Therapies has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

    Comment?

  4. Critical Analysis: Homology MedicinesRead the original story w/Photo

    14 hrs ago | Daily Political

    Homology Medicines and Aquinox Pharmaceuticals are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation. Homology Medicines currently has a consensus price target of $27.63, suggesting a potential upside of 10.59%.

    Comment?

  5. Contrasting Taxus Cardium Pharmaceuticals GroupRead the original story w/Photo

    14 hrs ago | AmericanBankingNews.com

    Taxus Cardium Pharmaceuticals Group and BioCardia are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. 0.1% of BioCardia shares are held by institutional investors.

    Comment?

  6. Reviewing BioCardiaRead the original story w/Photo

    14 hrs ago | AmericanBankingNews.com

    BioCardia and Acorda Therapeutics are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Acorda Therapeutics has a consensus target price of $25.75, suggesting a potential upside of 39.26%.

    Comment?

  7. Team uses gene editing to personalize clinical care for family with cardiomyopathyRead the original story w/Photo

    16 hrs ago | PhysOrg Weblog

    A little over a year ago, a 65-year-old woman with severe hypertrophic cardiomyopathy-a condition in which the heart's muscle becomes abnormally thick, potentially causing dangerous irregular heartbeats-had her genes sequenced before her first visit to the Penn Center for Inherited Cardiac Disease. In the sequence, the patient's care team identified a variant in a gene called TNNT2, which is associated with this type of heart disease.

    Comment?

  8. Why You Shouldn't Worry Too Much About Designer BabiesRead the original story w/Photo

    17 hrs ago | Bad Astronomy Blog

    When Adam Nash was still an embryo, living in a dish in the lab, scientists tested his DNA to make sure it was free of Fanconi anemia , the rare inherited blood disease from which his sister Molly suffered. They also checked his DNA for a marker that would reveal whether he shared the same tissue type.

    Comment?

  9. Flow Cytometry Market: Rise in Chronic Disease Occurrences Increases Cytometry UtilizationRead the original story w/Photo

    17 hrs ago | SBWire

    The global Flow Cytometry Market depicts the presence of a highly consolidated market, says Transparency Market Research on the basis of a recently published report. Such a consolidated presence mainly exists owing to a handful of players accounting for at least half the market shares in 2016.

    Comment?

  10. Ezogabine treatment shown to reduce motor neuron excitability in ALS patientsRead the original story w/Photo

    18 hrs ago | PhysOrg Weblog

    Brian Wainger, MD, Ph.D., of the Healey Center for ALS at Massachusetts General Hospital presented initial, top-level results of a recently completed phase 2 clinical trial of ezogabine on December 9 at the Motor Neurone Disease Association annual meeting in Glasgow, Scotland. The trial met its primary goal of measuring a reduction in motor neuron excitability in people with amyotrophic lateral sclerosis following treatment.

    Comment?

  11. Shame, Scandal Plague Healthcare Providers In 2018Read the original story w/Photo

    18 hrs ago | Forbes.com

    Fall was a rough season for the prestigious Memorial Sloan Kettering Cancer Center. In October, its chief executive Dr. Craig B. Thompson was forced to resign from the boards of Merck and Charles River Laboratories after investigations by The New York Times turned up " " with drug companies.

    Comment?

  12. Trump administration halts study using fetal tissue to find 'cure for HIV'Read the original story w/Photo

    21 hrs ago | Bangor Daily News

    ... armamentarium." Hasenkrug was not available for comment. Greene and Irving Weissman, a pioneer in stem cell research at Stanford University, said government officials imposed a gag order on him. An NIH spokeswoman said that when the HHS began its ...

    Comment?

  13. Nobel laureate Blackburn unexpectedly retiring as president of the Salk InstituteRead the original story w/Photo

    Yesterday | The San Diego Union-Tribune

    Nobel laureate Elizabeth Blackburn will step down as president of the Salk Institute at the end of next summer. Nobel laureate Elizabeth Blackburn is unexpectedly retiring as president of the Salk Institute in La Jolla , two years after taking over a research center that's been roiled by accusations of gender discrimination.

    Comment?

  14. Immune genes are primed for robust transcription by proximal long...Read the original story w/Photo

    Yesterday | Nature Genetics

    Thank you for visiting nature.com. You are using a browser version with limited support for CSS.

    Comment?

  15. Penn team uses gene editing to personalize clinical care for family with cardiomyopathyRead the original story w/Photo

    Yesterday | EurekAlert!

    A little over a year ago, a 65-year-old woman with severe hypertrophic cardiomyopathy--a condition in which the heart's muscle becomes abnormally thick, potentially causing dangerous irregular heartbeats--had her genes sequenced before her first visit to the Penn Center for Inherited Cardiac Disease. In the sequence, the patient's care team identified a variant in a gene called TNNT2, which is associated with this type of heart disease.

    Comment?

  16. Cell-based therapy for Crohn's disease: time to consider optimizationRead the original story w/Photo

    Friday Dec 7 | Nature Reviews Gastroenterology and Hepatology

    Thank you for visiting nature.com. You are using a browser version with limited support for CSS.

    Comment?

  17. Trump administration stops study aimed at finding 'cure for HIV'Read the original story w/Photo

    Yesterday | Iol.co.za

    ... armamentarium." Hasenkrug was not available for comment. Greene and Irving Weissman, a pioneer in stem cell research at Stanford University, said government officials imposed a gag order on him. An NIH spokeswoman said that when the HHS began its ...

    Comment?

  18. Study evaluates placental mesenchymal stem cell sheets for myocardial repair and regenerationRead the original story w/Photo

    Yesterday | Medical News

    The placenta offers an abundant source of placenta-derived mesenchymal stem cells , which a new study has shown can readily form cell sheets that could be implanted in children with congenital heart defects and offer benefits for heart repair and regeneration compared to commonly used synthetic material-based scaffolds. Congenital heart disease is the leading cause of birth-defect-related illness and death.

    Comment?

  19. Research advances offer hope for patient-tailored AML treatmentRead the original story w/Photo

    Yesterday | Medical News

    Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia . Research on the drug responses of leukemia stem cells may reveal why some attempts to treat are not successful or why initially promising treatment results are not sustained.

    Comment?

  20. Athersys: A Lucrative China Stem Cell Licensing Deal Seems ImminentRead the original story w/Photo

    Yesterday | Seeking Alpha

    Athersys files 8-K extending Healios K.K.'s right of first refusal deadline by one week to December 14 for China rights to MultiStem. Mesoblast $40,000,000 upfront deal with China's Tasly Pharmaceutical Group for cardiovascular alliance has set the benchmark for what to look for.

    Comment?